Thu, 27 Oct 2011 | DIVISION SALE
GlaxoSmithKline is planning to sell a swathe of consumer health product lines by the end of this year with a combined value of £700 million.
Advisers to the sale have been brought in and are said to be in discussion about the process. Brands for sale are those considered to be non-core by the group, and include the weight loss drug Alli.
The products generate £500 million per year in sales, and GSK aims to sell the lines for more than three times this amount.
The valuation figure of £700 million takes into account the costs of acquisition and the marketing funds spent to increase sales. Any additional amount above this that may be achieved in the sale would be treated as profits.
To satisfy investors’ demands for returns, GSK increased its planned level of share buy-backs for this year to £2.3 billion.
Separately it has been reported that GSK performed strongly in the third quarter. Group revenues were up by 3 per cent to £7.1 billion. The diabetes drug Avandia, herpes drug Valtrex and pandemic products had dragged on its sales, but this has lessened more recently.
Utilising its fleet of special-purpose LGVs and vans, the company offers UK and international domestic and business removals; short- and long-term storage solutions, including self-storage facilities; UK-wide collections and deliveries for single and...
Provides a range of products and services to the construction, restoration and domestic roof contracting sectors, including slating, tiling and leadwork. Caters to a broad client base comprising commercial, industrial and private domestic clients. Ex...
The company specialises in thermal insulation and trace heating solutions, installing and maintaining a wide array of insulation types, fire protection and weatherproof coverings. The business effectively works on many properties, including retail ou...
04
|
Mar
|
UK administrations update: February 26 – March 4 | ADMINISTRATION
Since our last update, the following businesses have been co...
04
|
Mar
|
Phenna makes fourth acquisition of 2025 with Calibre deal | BUSINESS SALE
Nottingham-based Phenna Group has made its fourth acquisitio...
03
|
Mar
|
Everest Pharmacy snaps up five more pharmacies from peer Sykes | DIVISION SALE
Manchester-based Everest Pharmacy has bought five pharmacies...
20
|
Jul
|
GSK puts Horlicks up for sale following review of UK business | DIVISION SALE
Drugs giant Glaxosmithkline will sell its Horlicks business ...
07
|
Sep
|
Japanese company in takeover talks with GSK over drinks brands | BUSINESS SALE
Suntory Beverage & Food is in discussion with GlaxoSmithKlin...
25
|
Apr
|
GSK puts Lucozade and Ribena on the market | DIVISION SALE
It has been confirmed that Lucozade and Ribena are on the ma...
Business Sale Report is the complete resource for finding genuine acquisition opportunities.
Join today to receive:
All this and much more, including the latest M&A news and exclusive resources
Please choose your settings for this site below. For more information please read our Cookie Policy
These cookies are necessary for our website to function properly and provide you with access to all features.
These are analytics cookies that help us to improve the way our website works.
These are used to improve the functional performance of the website and make it easier for you to use.